Liz Barrett, UroGen CEO, at the 2019 Forbes Healthcare Summit (Steven Ferdman/Getty Images)

That pipeline Ab­b­Vie ac­quired in the $63B Al­ler­gan buy­out? It’s not do­ing so well

An­oth­er Al­ler­gan project picked up by Ab­b­Vie in their $63 bil­lion buy­out has turned sour.

Uro­Gen $URGN re­port­ed Thurs­day morn­ing that a Phase II study us­ing their RT­Gel prod­uct to ap­ply Botox to stop over­ac­tive blad­der and uri­nary in­con­ti­nence has failed. Ab­b­Vie had been in charge of the study af­ter com­plet­ing the Al­ler­gan deal a few months ago.

Uro­Gen ex­ecs pinned the blame on Botox, say­ing that the da­ta sug­gest that the wrin­kle ther­a­py hadn’t ef­fec­tive­ly per­me­at­ed the urothe­li­um, or blad­der wall, pre­vent­ing ef­fi­ca­cy. And they went on to tout their prod­uct, al­ready on the mar­ket for urothe­lial can­cer, as a win­ner.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.